K-Obesity Drug 'Efpeglenatide' Begins Prescriptions; Will Hanmi Pharm Spark a Rebound? [Stock+]
Predicted impact: Medium
Prescriptions of obesity drug begin; sales size unknown, earlier items only cited expectations, not launch.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.